DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia

Area of Science:

• Epigenetics
• Cancer Biology
• Hematology

Background:

• Many de novo acute myeloid leukemia (AML) cases lack cytogenetic aberrations.
• Epigenetic alterations, including DNA methylation changes and mutations in epigenetic modifier genes, are key drivers in AML.
• Somatic missense mutations in DNA methyltransferase 3A (DNMT3A) are found in approximately 20% of AML patients, but downstream targets remain unclear.

Purpose of the Study:

• To identify downstream genes affected by DNMT3A mutations in AML.
• To elucidate the molecular mechanisms linking DNMT3A mutations to leukemogenesis.
• To explore alternative pathways for oncogenic gene activation in AML independent of known fusion proteins.

Main Methods:

• Whole-genome bisulfite sequencing (WGBS) to assess DNA methylation patterns.
• DNA methylation microarrays for high-throughput methylation analysis.
• Transcriptional analysis to identify reactivated genes.

Main Results:

• Identified MEIS1, a leukemogenic HOX cofactor, as a key gene reactivated in DNMT3A-mutant AML.
• Demonstrated that MEIS1 reactivation is associated with promoter hypomethylation in these patients.
• Showed that DNMT3A mutations can mediate an oncogenic MEIS1-dependent transcriptional program.

Conclusions:

• DNMT3A mutations provide an alternative mechanism for MEIS1-driven leukemogenesis in AML.
• This pathway is independent of mixed lineage leukemia (MLL) fusions.
• Understanding this epigenetic mechanism offers new insights into AML pathogenesis and potential therapeutic targets.